Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival

M. Hajkova, T. Andrasina, P. Ovesna, T. Rohan, M. Dostal, V. Valek, L. Ostrizkova, S. Tucek, J. Sedo, I. Kiss

. 2022 ; 36 (5) : 2332-2341. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024586

BACKGROUND/AIM: To evaluate the prognostic value of Response Evaluation Criteria In Solid Tumors (RECIST), modified RECIST and volumetric analysis in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). PATIENTS AND METHODS: This single-center prospective cohort study included a total of 61 patients with HCC treated by transarterial chemoembolization (TACE). The response of TACE was evaluated on preprocedural and postprocedural CT by two radiologists using RECIST/mRECIST and volumetric response to treatment. Each response assessment method was used to classify the response as progressive disease, stable disease, partial response and complete response. Kaplan-Meier analysis with log-rank test was performed for each method to evaluate its ability to help predict overall survival and progression free survival. Interobserver variability and reproducibility was determined by the Pearson and Spearman correlation coefficients. RESULTS: The median overall survival was 17.1 months and the median progression-free survival was 11.1 months. Volumetric assessment was proved to be a prognostic factor for overall survival (p<0.01) and progression-free survival (p<0.001), contrasting with RECIST and mRECIST. All three methods featured very small interobserver variability (p<0.001 for Pearson and Spearman correlation coefficients). The patients classified as having stable disease had a 3.8-fold higher risk of death than the patients classified as having a complete/partial response (HR=3.82; 95% Confidence Interval (CI)=1.32-11.02; p=0.013) and a 4.5-fold higher risk of progression (HR=4.46; 95% CI=1.72-11.61; p=0.002). CONCLUSION: The prognostic value of volumetric analysis in patients with HCC treated by TACE appears to be superior to RECIST and mRECIST, with a real impact in everyday practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024586
003      
CZ-PrNML
005      
20221031100326.0
007      
ta
008      
221017s2022 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12964 $2 doi
035    __
$a (PubMed)36099102
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Hajkova, Monika $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival / $c M. Hajkova, T. Andrasina, P. Ovesna, T. Rohan, M. Dostal, V. Valek, L. Ostrizkova, S. Tucek, J. Sedo, I. Kiss
520    9_
$a BACKGROUND/AIM: To evaluate the prognostic value of Response Evaluation Criteria In Solid Tumors (RECIST), modified RECIST and volumetric analysis in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). PATIENTS AND METHODS: This single-center prospective cohort study included a total of 61 patients with HCC treated by transarterial chemoembolization (TACE). The response of TACE was evaluated on preprocedural and postprocedural CT by two radiologists using RECIST/mRECIST and volumetric response to treatment. Each response assessment method was used to classify the response as progressive disease, stable disease, partial response and complete response. Kaplan-Meier analysis with log-rank test was performed for each method to evaluate its ability to help predict overall survival and progression free survival. Interobserver variability and reproducibility was determined by the Pearson and Spearman correlation coefficients. RESULTS: The median overall survival was 17.1 months and the median progression-free survival was 11.1 months. Volumetric assessment was proved to be a prognostic factor for overall survival (p<0.01) and progression-free survival (p<0.001), contrasting with RECIST and mRECIST. All three methods featured very small interobserver variability (p<0.001 for Pearson and Spearman correlation coefficients). The patients classified as having stable disease had a 3.8-fold higher risk of death than the patients classified as having a complete/partial response (HR=3.82; 95% Confidence Interval (CI)=1.32-11.02; p=0.013) and a 4.5-fold higher risk of progression (HR=4.46; 95% CI=1.72-11.61; p=0.002). CONCLUSION: The prognostic value of volumetric analysis in patients with HCC treated by TACE appears to be superior to RECIST and mRECIST, with a real impact in everyday practice.
650    12
$a hepatocelulární karcinom $x diagnostické zobrazování $x terapie $7 D006528
650    12
$a chemoembolizace $x metody $7 D016461
650    _2
$a lidé $7 D006801
650    12
$a nádory jater $x terapie $7 D008113
650    _2
$a prospektivní studie $7 D011446
650    _2
$a reprodukovatelnost výsledků $7 D015203
655    _2
$a časopisecké články $7 D016428
700    1_
$a Andrasina, Tomas $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; andrasina.tomas@fnbrno.cz
700    1_
$a Ovesna, Petra $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Rohan, Tomas $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Dostal, Marek $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Department of Biophysics, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Valek, Vlastimil $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ostrizkova, Lenka $u Department of Hematooncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Tucek, Stepan $u Department of Hematooncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Sedo, Jiri $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Kiss, Igor $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
773    0_
$w MED00175831 $t In vivo $x 1791-7549 $g Roč. 36, č. 5 (2022), s. 2332-2341
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36099102 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100324 $b ABA008
999    __
$a ok $b bmc $g 1854357 $s 1175876
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 36 $c 5 $d 2332-2341 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace